4.41
price up icon2.32%   0.10
after-market Handel nachbörslich: 4.39 -0.02 -0.45%
loading
Schlusskurs vom Vortag:
$4.31
Offen:
$4.35
24-Stunden-Volumen:
4.12M
Relative Volume:
1.42
Marktkapitalisierung:
$628.67M
Einnahmen:
$181.41M
Nettoeinkommen (Verlust:
$-59.56M
KGV:
-10.50
EPS:
-0.42
Netto-Cashflow:
$-38.83M
1W Leistung:
+9.70%
1M Leistung:
-20.97%
6M Leistung:
+36.53%
1J Leistung:
+152.00%
1-Tages-Spanne:
Value
$4.30
$4.5401
1-Wochen-Bereich:
Value
$4.00
$4.5401
52-Wochen-Spanne:
Value
$1.71
$6.07

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name
Firmenname
Xeris Biopharma Holdings Inc
Name
Telefon
844-445-5704
Name
Adresse
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Name
Mitarbeiter
394
Name
Twitter
@XerisPharma
Name
Nächster Verdiensttermin
2024-12-08
Name
Neueste SEC-Einreichungen
Name
XERS's Discussions on Twitter

Vergleichen Sie XERS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
XERS
Xeris Biopharma Holdings Inc
4.41 628.67M 181.41M -59.56M -38.83M -0.42
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-11 Herabstufung Piper Sandler Overweight → Neutral
2024-03-28 Eingeleitet Oppenheimer Outperform
2023-08-28 Eingeleitet Craig Hallum Buy
2022-10-21 Eingeleitet Jefferies Buy
2022-04-28 Eingeleitet Craig Hallum Buy
2021-11-17 Eingeleitet SVB Leerink Outperform
2021-10-29 Eingeleitet H.C. Wainwright Buy
2021-04-07 Fortgesetzt RBC Capital Mkts Outperform
2020-02-18 Eingeleitet Piper Sandler Overweight
2018-07-16 Eingeleitet Jefferies Buy
2018-07-16 Eingeleitet Leerink Partners Outperform
2018-07-16 Eingeleitet RBC Capital Mkts Outperform
Alle ansehen

Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten

pulisher
08:23 AM

Recent Insider Activity Suggests Potential Gains for Xeris Biopharma Holdings Inc (XERS) - knoxdaily.com

08:23 AM
pulisher
Apr 27, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Bought by Russell Investments Group Ltd. - Defense World

Apr 27, 2025
pulisher
Apr 26, 2025

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit - Yahoo

Apr 26, 2025
pulisher
Apr 25, 2025

Xeris Biopharma Holdings Inc’s Banking’s 100-Day Moving Average at 3.96: Will the Stock Break Through? - investchronicle.com

Apr 25, 2025
pulisher
Apr 25, 2025

Xeris Biopharma Holdings Inc (XERS) Performance and Fundamentals Dashboard tells a completely different story - Sete News

Apr 25, 2025
pulisher
Apr 23, 2025

Understanding the Risks of Investing in Xeris Biopharma Holdings Inc (XERS) - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Geode Capital Management LLC - Defense World

Apr 23, 2025
pulisher
Apr 22, 2025

Is Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires? - Insider Monkey

Apr 22, 2025
pulisher
Apr 22, 2025

10 Best Multibagger Penny Stocks to Buy According to Billionaires - Insider Monkey

Apr 22, 2025
pulisher
Apr 22, 2025

Are Xeris Biopharma Holdings Inc (XERS) shares a good deal now? - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

Market Watch: Xeris Biopharma Holdings Inc (XERS)’s Noteworthy Drop, Closing at 4.02 - DWinneX

Apr 22, 2025
pulisher
Apr 21, 2025

JPMorgan Chase & Co. Has $3.54 Million Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Apr 21, 2025
pulisher
Apr 21, 2025

Alliancebernstein L.P. Reduces Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Apr 21, 2025
pulisher
Apr 17, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Large Growth in Short Interest - Defense World

Apr 17, 2025
pulisher
Apr 15, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Vanguard Group Inc. - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Raymond James Financial Inc. Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Wellington Management Group LLP Sells 6,532 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Purchased by Prudential Financial Inc. - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Holdings Lowered by Corebridge Financial Inc. - Defense World

Apr 12, 2025
pulisher
Apr 02, 2025

Xeris Biopharma Holdings Inc [XERS] stock was sold by Hecht Beth at the price of US$0.22 million - knoxdaily.com

Apr 02, 2025
pulisher
Mar 31, 2025

AIGH Capital Management LLC Purchases 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat

Mar 31, 2025
pulisher
Mar 31, 2025

Auto-Injectors Market Growth in Future Scope 2025-2032 | Sanofi - openPR

Mar 31, 2025
pulisher
Mar 28, 2025

Xeris Pharmaceuticals Announces Board Changes with New Appointment - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Xeris Biopharma reshuffles board, appoints new director By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Xeris Announces Changes To Its Board Of Directors - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Xeris Biopharma reshuffles board, appoints new director - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Xeris Announces Changes to Its Board of Directors - Business Wire

Mar 28, 2025
pulisher
Mar 27, 2025

Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? - Insider Monkey

Mar 27, 2025
pulisher
Mar 25, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by Bank of New York Mellon Corp - Defense World

Mar 25, 2025
pulisher
Mar 23, 2025

Don't Ignore The Insider Selling In Xeris Biopharma Holdings - simplywall.st

Mar 23, 2025
pulisher
Mar 23, 2025

Connor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Xeris Biopharma (NASDAQ:XERS) Stock Price Up 4.9% – Here’s Why - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock - Investing.com India

Mar 22, 2025
pulisher
Mar 21, 2025

Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Xeris Pharmaceuticals stock hits 52-week high at $5.54 - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Xeris Pharmaceuticals stock hits 52-week high at $5.54 By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 20, 2025

Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

Xeris Biopharma (NASDAQ:XERS) Reaches New 52-Week High – Time to Buy? - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game - Insider Monkey

Mar 19, 2025
pulisher
Mar 19, 2025

Xeris enters a whole new market for one of its main pharma offerings - Crain's Chicago Business

Mar 19, 2025
pulisher
Mar 19, 2025

Is XERS Stock a Good Buy in 2025? Key Insights for Investors - Stocks Telegraph

Mar 19, 2025
pulisher
Mar 18, 2025

12 Best Stocks to Invest in for a Stock Market Game - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent - Investing.com Australia

Mar 18, 2025
pulisher
Mar 17, 2025

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid - BioSpace

Mar 17, 2025
pulisher
Mar 17, 2025

Xeris Biopharma Says US FDA Approves Gvoke VialDx for Diagnostic Use -March 17, 2025 at 08:33 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent By Investing.com - Investing.com South Africa

Mar 17, 2025

Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Kapitalisierung:     |  Volumen (24h):